A PHASE 2, OPEN-LABEL, SINGLE-ARM, COHORT STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF SPARSENTAN TREATMENT IN PEDIATRIC SUBJECTS WITH SELECTED PROTEINURIC GLOMERULAR DISEASES (EPPIK)
Administered By
Awarded By
Contributors
- Gbadegesin, Rasheed Adebayo Principal Investigator
Start/End
- November 18, 2021 - October 31, 2023